Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/118403
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Non-canonical AR activity facilitates endocrine resistance in breast cancer
Author: Chia, K.
Milioli, H.
Portman, N.
Laven-Law, G.
Coulson, R.
Yong, A.
Segara, D.
Parker, A.
Caldon, C.
Deng, N.
Swarbrick, A.
Tilley, W.
Hickey, T.
Lim, E.
Citation: Endocrine-Related Cancer, 2019; 26(2):251-264
Publisher: Bioscientifica Ltd.
Issue Date: 2019
ISSN: 1351-0088
1479-6821
Statement of
Responsibility: 
KeeMing Chia, Heloisa Milioli, Neil Portman, Geraldine Laven-Law, Rhiannon Coulson, Aliza Yong, Davendra Segara, Andrew Parker, Catherine E Caldon, Niantao Deng, Alexander Swarbrick, Wayne D Tilley, Theresa E Hickey and Elgene Lim
Abstract: The role of androgen receptor (AR) in endocrine-resistant breast cancer is controversial and clinical trials targeting AR with an AR antagonist (e.g., enzalutamide) have been initiated. Here, we investigated the consequence of AR antagonism using in vitro and in vivo models of endocrine resistance. AR antagonism in MCF7-derived tamoxifen-resistant (TamR) and long-term estrogen-deprived breast cancer cell lines were achieved using siRNA-mediated knockdown or pharmacological inhibition with enzalutamide. The efficacy of enzalutamide was further assessed in vivo in an estrogen-independent endocrine-resistant patient-derived xenograft (PDX) model. Knockdown of AR inhibited the growth of the endocrine-resistant cell line models. Microarray gene expression profiling of the TamR cells following AR knockdown revealed perturbations in proliferative signaling pathways upregulated in endocrine resistance. AR loss also increased some canonical ER signaling events and restored sensitivity of TamR cells to tamoxifen. In contrast, enzalutamide did not recapitulate the effect of AR knockdown in vitro, even though it inhibited canonical AR signaling, which suggests that it is the non-canonical AR activity that facilitated endocrine resistance. Enzalutamide had demonstrable efficacy in inhibiting AR activity in vivo but did not affect the growth of the endocrine-resistant PDX model. Our findings implicate non-canonical AR activity in facilitating an endocrine-resistant phenotype in breast cancer. Unlike canonical AR signaling which is inhibited by enzalutamide, non-canonical AR activity is not effectively antagonized by enzalutamide, and this has important implications in the design of future AR-targeted clinical trials in endocrine-resistant breast cancer.
Keywords: Endocrine resistance; breast cancer; AR; enzalutamide; PDX
Rights: © 2019 Society for Endocrinology. Published by Bioscientifica Ltd.
RMID: 0030106083
DOI: 10.1530/ERC-18-0333
Grant ID: http://purl.org/au-research/grants/nhmrc/1008349
http://purl.org/au-research/grants/nhmrc/1084416
http://purl.org/au-research/grants/nhmrc/1093801
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.